AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Collaboration to develop antibodies for cancer, autoimmune diseases announced.
2004 DEC 29 - (NewsRx.com & NewsRx.net) -- Xencor announced a license and collaboration agreement with Genentech, Inc. (DNA) to create next-generation therapeutic antibodies for cancer and autoimmune diseases.
Under the terms of the agreement, Xencor will grant to Genentech an exclusive, worldwide license to use Xencor's XmAb technology to develop and commercialize products directed against 2 clinically and commercially validated antibody targets, CD20 and Her2, and a third undisclosed antigen. Rituxan (rituximab) targets CD20 and is marketed by Genentech and Biogen-Idec in the United States, Zenyaku in Japan and Roche in the rest of the world. Herceptin (trastuzumab), which is marketed by Genentech in the United States and Roche in the rest of the world, targets the Her2 protein.
The XmAb technology consists of a suite of proprietary engineered antibody Fc domains that can be incorporated into therapeutic candidates to potentially recruit the immune system's effector functions for the treatment of disease.
Xencor will receive an upfront fee of $5 million and annual ...
- Xencor obtains United States patent.
- Newspaper article from: BIOTECH Patent News April 1, 2008 700+ words
Xencor (Monrovia, CA) has patented the use of protein design automation (PDA) to generate computationally prescreened secondary libraries of proteins, and to methods and compositions utilizing the libraries. (US 7,379,822)
- Xencor and Genentech to Collaborate to Develop Next-Generation Antibody...
- Press release article from: Business Wire December 1, 2004 700+ words
...terms of the agreement, Xencor will grant to Genentech...worldwide license to use Xencor's XmAb technology...Biogen-Idec in the United States, Zenyaku in Japan and...by Genentech in the United States and Roche in the rest...treatment of disease. Xencor will receive an ...
- Xencor Expands Management Team; Leverages $50 Million Series C Financing to...
- Press release article from: Business Wire July 19, 2001 700+ words
...technologies and the novel compounds Xencor identifies using them, and...property." Dr. Radany joins Xencor from Caliper Technologies Corp...as Patent Examiner with the United States Patent and Trademark Office...Pennsylvania State University. Xencor, a privately held company...
- Xencor Receives Patent for its Proprietary Antibody Fc Optimization Technology.
- Press release article from: Business Wire January 9, 2008 700+ words
MONROVIA, Calif. -- Xencor, Inc., a company developing...received a patent from the United States Patent and Trademark Office...patent applications covering Xencor's XmAb[TM] antibody Fc...selectively engineered Fc domains. Xencor's engineered Fc domains have...
- Xencor Receives Advanced Technology Program Grant for Safer Protein...
- Press release article from: Business Wire October 9, 2002 700+ words
...Design Automation platform Xencor's PDA technology is the first...optimization and sequence design. Xencor uses the information embedded...based economic benefits for the United States. The awards are made on the...www.atp.nist.gov. Xencor discovers and develops protein...
- Xencor Initiates Phase I Clinical Trial with XmAb2513 in Lymphoma.
- Press release article from: Business Wire February 11, 2008 700+ words
...D., Chief Medical Officer of Xencor. "This is a very promising compound...percent of all cases of cancer in the United States. Of the nearly 500,000 Americans...are beginning to increase. About Xencor, Inc. Xencor, Inc. engineers...
- Jeffrey D. Bloss, M.D., Joins Xencor as Chief Medical Officer.
- Press release article from: Business Wire October 25, 2007 700+ words
...is a pivotal appointment for Xencor. He has a proven track record...D., president and CEO of Xencor. "His medical background...medical positions with the United States Air Force Medical Corps. He...from Juniata College. "Xencor's unique approach to antibody...
- Researchers from Xencor, Inc. publish new studies and findings in the area of...
- Newspaper article from: Biotech Week June 10, 2009 700+ words
...Zalevsky and colleagues, Xencor, Inc (see also Life Sciences...information, contact J. Zalevsky, Xencor Inc., 111 W Lemon Avenue...DC 20036, USA. Keywords: United States, Life Sciences, Antitumor...Xenograft, Xenotransplantion, Xencor, Inc. This article was prepared...
- Research conducted at Xencor, Inc. has updated our knowledge about leukemia.
- Newspaper article from: Blood Weekly November 27, 2008 700+ words
...M. Horton and colleagues, Xencor, Inc (see also Leukemia...contact E.A. Zhukovsky, Xencor Inc., 111 W Lemon Avenue...19106-4404, USA. Keywords: United States, Biological Therapy, Biotechnology...Lymphoma, Oncology, Treatment, Xencor, Inc. This article was prepared...
- Studies from Xencor, Inc. yield new information about immunology.
- Newspaper article from: Blood Weekly November 6, 2008 700+ words
...wrote S.Y. Chu and colleagues, Xencor, Inc (see also Immunology). The researchers...additional information, contact S.Y. Chu, Xencor, Inc., 111 W Lemon Avenue, Monrovia...Oxford OX5 1GB, England. Keywords: United States, Bioengineering, Biomedical Engineering...
Source: HighBeam Research, Collaboration to develop antibodies for cancer, autoimmune diseases...